Abstracts tagged "gout"

Abstract Number: 0668 • ACR Convergence 2021
Patient Perspectives and Preferences Regarding Gout and Gout Management: Impact on Adherence
Min Kyung Chung¹, Sung Soo Kim², Yun-Hong Cheon³, Seung Jae Hong⁴, Hyo Jin Choi⁵, Mi Ryoung Seo⁵, Ji Won Hwang⁶, Joong Kyong Ahn⁷, Sang-Heon Lee⁸, Hong Ki Min⁸, Hoon-Suk Cha⁹, Shin-Seok Lee¹⁰, Jennifer Lee¹¹, Ki Won Moon¹², Chang-Keun Lee¹³, Hyun-Ok Kim¹⁴, Young Sun Seo¹⁵, Seung-Cheol Shim¹⁶, Seong Wook Kang¹⁶, Jinhyun Kim¹⁶, Sang Tae Choi¹⁷, Jung Soo Song¹⁷ and Jisoo Lee¹, ¹Ewha Womans University College of Medicine, Seoul, Republic of Korea, ²Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, Republic of Korea, ³Gyeongsang National University Hospital, Jinju, Republic of Korea, ⁴Kyung Hee University Hospital, School of Medicine, Kyung Hee University, Seoul, Republic of Korea, ⁵Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea, ⁶Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Republic of Korea, ⁷Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, ⁸Konkuk University Medical Center, Seoul, Republic of Korea, ⁹Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, ¹⁰Chonnam National University Medical School & Hospital, Gwangju, Republic of Korea, ¹¹Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea, ¹²Kangwon National University School of Medicine, Chuncheon, Republic of Korea, ¹³Asan Medical Center, SEOUL, Republic of Korea, ¹⁴Gyeongsang National University College of Medicine, Changwon, Republic of Korea, ¹⁵Gyeongsang National University Hospital, Changwon, Republic of Korea, ¹⁶Chungnam National University, Chungnam National University Hospital, Daejeon, Republic of Korea, ¹⁷Chung-Ang University School of Medicine, Seoul, Republic of Korea
Background/Purpose: Patient-centered management is becoming increasingly important in gout, but there are limited studies exploring patients’ perspectives and preferences. We aimed to investigate patients’ perspectives…
Abstract Number: 1095 • ACR Convergence 2021
Improved Arthrocentesis and Fluid Yield of the Non-Effusive Knee Using Pneumatic Compression
Ahsan Iqbal¹, Sumir Brahmbhatt¹, Maheswari Muruganandam², David Cisneros³, Adnan Kiani², Fatemeh Farshami⁴, Jaren Trost⁵, N. Suzanne Emil², Sharon Nunez¹ and Wilmer Sibbitt², ¹UNM, Albuquerque, NM, ²University of New Mexico, Albuquerque, NM, ³University of New Mexico School of Medicine, Albuquerque, NM, ⁴University of New Mexico, Albuquerque, MD, ⁵Optum, Albuquerque, NM
Background/Purpose: Arthrocentesis is critical for diagnosis and therapy of joint disease; however, it is very difficult to obtain diagnostic fluid from an arthritic but clinically…
Abstract Number: 1580 • ACR Convergence 2021
Whole Blood Gene Expression and eQTL Analysis Implicate GGT7 and FADS2 in Gout Pathogenesis
Richard Reynolds¹, Riku Takei¹, Jeffrey Edberg¹, Nicholas Sumpter¹, Tony Merriman² and Megan Leask¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Dunedin, New Zealand
Background/Purpose: Gene expression studies of whole blood represent a powerful approach for understanding the pathogenesis of gout because differentially expressed transcripts may reflect the activation…
Abstract Number: 0669 • ACR Convergence 2021
Early-Onset Gout (EOG) Patients Are an Important and Recalcitrant Phenotype Warranting Further Investigation: A Systematic Review
Anthony Amatucci¹, Brian LaMoreaux² and David Bulbin³, ¹Horizon Therapeutics, West Orange, NJ, ²Horizon Therapeutics plc, Deerfield, IL, ³Geisinger Health System, Danville, PA
Background/Purpose: Data suggests that the number of patients with early-onset gout (EOG), defined as patients under the age of 40 years, is increasing1. There is…
Abstract Number: 1099 • ACR Convergence 2021
Characteristics and Outcomes of Myocardial Infarction in Patients with Rheumatoid Arthritis, Systemic Lupus Erythematosus, Systemic Sclerosis, Gout and Osteoarthritis Patients Using the National Inpatient Sample Database from 2002-2018
Sonia Gupta¹, Vinay thallapally², Sarah Aurit², Rouhin sen³ and Joseph Nahas², ¹Creighton University School of Medicine, Omaha, NE, ²Creighton University, Omaha, NE, ³Colorado University Anschutz Medical Campus, Denver, CO
Background/Purpose: Patients with the autoimmune rheumatic disease have an increased risk of acute myocardial infarction (MI). Our study was designed to compare the prevalence, characteristics…
Abstract Number: 1581 • ACR Convergence 2021
Genetic Effects on the Transition from Hyperuricemia to Gout
Nicholas Sumpter¹, Riku Takei¹, Richard Reynolds¹ and Tony Merriman², ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Dunedin, New Zealand
Background/Purpose: There is clear evidence of genetic control of hyperuricemia resulting in increased gout risk, however genetic control of the transition from hyperuricemia to gout…
Abstract Number: 0671 • ACR Convergence 2021
Concomitant Immunomodulation and Pegloticase Therapy: Experiences with a Variety of Immunomodulatory Agents in Two Community Rheumatology Practices
Aaron Broadwell¹, John Albert², Brian LaMoreaux³ and Lissa Padnick-Silver³, ¹Rheumatology and Osteoporosis Specialists, Shreveport, LA, ²Rheumatic Disease Center, Milwaukee, WI, ³Horizon Therapeutics plc, Deerfield, IL
Background/Purpose: Patients with uncontrolled or refractory gout have heavy disease burden,1 but few treatment options. Pegloticase is effective for lowering serum urate (SU) in these…
Abstract Number: 1184 • ACR Convergence 2021
Voluntary Online Gout Module: Housestaff Utilization and Efficacy
Sarah Tarplin¹, Susan Kroop² and Catherine Deffendall², ¹Vanderbilt Universty Medical Center, nashville, TN, ²Vanderbilt University, Nashville, TN
Background/Purpose: All Internal Medicine (IM) physicians should be competent in gout diagnosis and management. The purpose of this study is to assess learner engagement with…
Abstract Number: 1895 • ACR Convergence 2021
Achievement of Target Serum Uric Acid Among Gout Patients Treated with Long-term Urate Lowering Therapy in the ACR’s Rheumatology Informatics System for Effectiveness (RISE) Registry
Nevin Hammam, Jing Li, Julia L Kay, Jinoos Yazdany and Gabriela Schmajuk, University of California San Francisco, San Francisco, CA
Background/Purpose: The American College of Rheumatology’s (ACR) 2012 guidelines for the management of gout recommend using a treat-to-target (T2T) approach to lower serum uric acid…
Abstract Number: 0672 • ACR Convergence 2021
Does Obesity Affect Gout Risk Differently Among Genetically Predisposed Individuals?: Sex-Specific Prospective Cohort Study Findings over >32 Years
Chio Yokose¹, Natalie McCormick², Na Lu³, Amit Joshi² and Hyon K. Choi⁴, ¹Massachusetts General Hospital, Waltham, MA, ²Massachusetts General Hospital, Boston, MA, ³Arthritis Research Canada, Vancouver, BC, Canada, ⁴Massachusetts General Hospital, Lexington, MA
Background/Purpose: Two recent analyses of the Global Burden of Disease Study reported on the rising global burden of gout (Safiri A&R 2020, Xia Rheumatology 2020).…
Abstract Number: 1449 • ACR Convergence 2021
Is Repeat Serum Urate Testing Superior to a Single Test to Predict Incident Gout over Time?
Sarah Stewart¹, Amanda Phipps-Green², Gregory Gamble¹, Lisa Stamp³, William Taylor⁴, Tuhina Neogi⁵, Tony Merriman⁶ and Nicola Dalbeth¹, ¹University of Auckland, Auckland, New Zealand, ²University of Otago Dunedin, Dunedin, New Zealand, ³University of Otago, Christchurch, Christchurch, New Zealand, ⁴University of Otago Wellington, Auckland, New Zealand, ⁵Boston University School of Medicine, Boston, MA, ⁶University of Alabama at Birmingham, Dunedin, New Zealand
Background/Purpose: Elevated serum urate is the most important risk factor for developing gout. However, in longitudinal cohort studies, a small proportion of people with normal…
Abstract Number: 1897 • ACR Convergence 2021
A Randomized Double-Blind Controlled Trial of Intensive Serum Urate Lowering with Oral Urate-Lowering Therapy for Erosive Gout
Nicola Dalbeth¹, Anthony Doyle¹, Karen Billington¹, Gregory Gamble¹, Paul Tan¹, Kieran Latto¹, Trish Parshu Ram¹, Ravi Narang¹, Rachel Murdoch¹, David Bursill¹, Borislav Mihov¹, Lisa Stamp² and Anne Horne¹, ¹University of Auckland, Auckland, New Zealand, ²University of Otago, Christchurch, Christchurch, New Zealand
Background/Purpose: Bone erosion is a common consequence of tophaceous gout, and leads to joint deformity and disability. In small case series, intensive urate-lowering with intravenous…
Abstract Number: 0673 • ACR Convergence 2021
The Impact of Allopurinol on Blood Pressure and Renal Outcome in Gout Patients: A Retrospective Study
Aniqa Faraz¹, Sabeeh Islam², Joseph Grisanti³ and Shumaila Iqbal⁴, ¹University at Buffalo-CHS Sisters of Charity, Grand Island, NY, ²Brigham and Women's Hospital Cardiology, Boston, MA, ³Buffalo Rheumatology & Medicine, Orchard Park, NY, ⁴University of Cincinnati, Cincinnati, OH
Background/Purpose: The relationship between change in serum uric acid level and progression of chronic kidney disease and hypertension is still conflicting. In this study, we…
Abstract Number: 1529 • ACR Convergence 2021
Effectiveness and Safety of Pegloticase with Concomitant Immunomodulatory Therapy
Huifeng Yun¹, Brian LaMoreaux², Lang Chen³, Stephanie Ledbetter³, Megan Francis-Sedlak², Kenneth Saag³, Ted Mikuls⁴ and Jeffrey Curtis⁵, ¹University of Alabama Birmingham, Birmingham, AL, ²Horizon Therapeutics plc, Deerfield, IL, ³University of Alabama at Birmingham, Birmingham, AL, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Oral urate-lowering therapy (ULT) is one of the primary treatments for gout. Unfortunately, a proportion of patients with advanced gout are resistant to oral…
Abstract Number: 1899 • ACR Convergence 2021
Mortality in Patients with Sub-Optimally Treated Gout in the Veteran’s Health Administration: A National Retrospective Cohort Study
Lindsay Helget¹, Bryant England¹, Punyasha Roul¹, Harlan Sayles¹, Alison Petro¹, Tuhina Neogi² and Ted Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE, ²Boston University School of Medicine, Boston, MA
Background/Purpose: Patients with gout have an increased risk of mortality. Current ACR guidelines for the treatment of gout recommend a treat-to-target approach with titration of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].